The activities of erythrocyte phosphoribosyl pyrophosphate (PRPP) synthetase and glutathione reductase (GTR) were studied in 26 patients with primary gout who were receiving no treatment or treatment with either allopurinol or azapropazone, and compared with the activity in a group of healthy controls. The activity of PRPP synthetase was significantly higher in the gout group and was not influenced by either drug. No significant difference in the activity of GTR was observed. The failure of either drug to suppress the increased activity of PRPP synthetase associated with gout is discussed.
The biochemical observation most frequently associated with primary gout is the excessive production of uric acid, which may be attributed to the formation of increased amounts of phosphoribosyl pyrophosphate (PRPP). An excessive amount of PRPP not only stimulates purine biosynthesis but nullifies the allosteric control mechanism of this metabolic pathway by the purine nucleotides. The latter are feedback inhibitors of the enzyme PRPP glutamine amidotransferase (EC 2.4.2.14), which catalyses the first stage of de novo purine biosynthesis. An increase of erythrocyte PRPP synthetase (EC 2.7.6.1) has been reported in individuals with familial gout' 2 and in 54 patients with primary gout3 when compared with healthy individuals. The effect of treatment on the activity of this enzyme has not to our knowledge been studied.
Conflicting reports of the changes in erythrocyte GTR (EC 1.6.4.2) activity in primary gout compared with healthy individuals have been published. An increase in enzymic activity has been reported by Long, 4 The mean age of the eight male controls was 48 years (range 46-51).
SAMPLE COLLECTION
The subjects fasted overnight for at least 10 hours. Whole blood (10 ml) was collected by venepuncture into plastic tubes containing lithium heparin and dispatched to the laboratory, where they were processed within three hours of collection. The samples were centrifuged at 1000 g for 10 min and the plasma and buffy coat separated. The packed red cells were washed thrice with physiological saline and centrifuged at 1000 g for 10 min. After the final wash the original volume of blood was restored by adding physiological saline to the packed cells.
PREPARATION OF HAEMOLYSATE
One millilitre of the homogeneous cell suspension was added to 8 ml of ice cold water and mixed for 10 min. Eight millilitres of phosphate buffer (90 mmol/l, pH 7-4) containing disodium ethylenediaminetetra-acetate (EDTA) (4 mmol/l) was added to the 'laked' cells and the mixing continued for 10 min followed by centrifugation at 1000 g for 10 min. Before the PRPP synthetase assay the supernatant was diluted 1:8-5 with phosphate buffer (67.5 mmol/l, pH 7.75) containing disodium adenosine triphosphate (ATP) and MgCl2 to give a haemolysate preparation of 0-65 mmolI ATP, 1 25 mmolIl Mg2+, 0-22 mmol/l EDTA in 64 5 mmol/l phosphate buffer (pH 7-75). The protein content of the supernatant of the initial 1 in 17 haemolysate was measured on a Guildford Staser III using the biuret reagent and a standard reference serum.
ENZYME ASSAYS
All assays were performed on the day of collection (Tables 1 and 2 ) the reduction in glutathione reductase activity in gout appears to be insignificant (p=0.2). Three of the untreated gout patients, however, had very high glutathione reductase levels (> 175 compared with a mean value of 78-9 nmol/mg protein/h). If these high values are discarded from the statistical analysis a significant reduction in enzymic activity for the gout patients (p=0.001, Table 2 ) is observed. It is difficult at this stage to justify rejection of these very high values in these untreated gout patients, but there is certainly a skew distribution of glutathione reductase activities in healthy populations3 "' which may, in time, be attributable to the presence of genetic variants of the enzyme. This seems to be improbable in our three patients since their very high enzymic activities returned to normal levels when treatment was resumed. Such a finding also eliminates age or sex as possible causes of the high activities, but these results demand a wider survey.
It is apparent from the results given in Table 3 that the serum uric acid concentration in patients with gout is reduced by chemotherapy using either allopurinol or azapropazone, but in this study the latter appears to be more effective than allopurinol.
The lipid profile of the gout population shows a significant amount of type IV hyperlipidaemia (seven of the 26 patients). In the normal control group seven subjects were normal and one had mild type lIb. It is not surprising that the mean serum cholesterol level of the patients with gout was neither affected by treatment nor differed appreciably from the control mean (Table 4 ). In contrast, the mean serum triglyceride concentration of the gout population was significantly higher than that found in the control group (Table 4) . These findinis are in agreement with those of previous workers, 1"-4 though we do not find an increase in type IlIb hyperlipidaemia in our gout population as reported by Naito and MacKenzie. '5 Our results thus suggest that in a well documented gout population the activity of PRPP synthetase is increased and could be one factor in producing the hyperuricaemia seen in these patients. The exact mechanism for this increase, which is unaffected by allopurinol or azapropazone, is not obvious from the present study, but the existence of a genetic variant of the enzyme cannot be excluded without further investigation. A reduced activity of glutathione reductase has been previously shown and may be a secondary effect associated with inflammation. This hypothesis is currently being investigated. 
